Virus Patents (Class 514/934)
-
Patent number: 6350467Abstract: A method of increasing glutathione levels in mammalian cells comprising administering an oral bolus of encapsulated pharmaceutically stabilized glutathione in a rapidly dissolving formulation to a mammal on an empty stomach. Pharmaceutical formulations including glutathione are also disclosed.Type: GrantFiled: June 28, 1999Date of Patent: February 26, 2002Assignee: Antioxidant Pharmaceuticals Corp.Inventors: Harry B. Demopoulos, Myron L. Seligman
-
Patent number: 6284249Abstract: The invention concerns a pharmaceutical composition for treating or preventing C hepatitis (HCV), induced infections, which in a preferred embodiment, comprises a main active principle, (i) a fusion polypeptide, including the HCV capsid polypeptide (C191) and polypeptide coat (E1) and in which at least one cleavage site 173/174 and 191/192 has been made inoperative by mutation; (ii) an equimolar mixture of the C191 polypeptide of which the cleavage site 173/174 has been made inoperative and of the E1 polypeptide (mixture equivalent to the fusion polypeptide); or (iii) a DNA molecule coding for this fusion polypeptide. Products (i) to (iii) are characterized in that the C191 element is incapable of regulating the functioning of the genes, in particular of causing them to interact. Such a composition can also include any form equivalent to the products described above.Type: GrantFiled: September 2, 1999Date of Patent: September 4, 2001Assignee: Pasteur Merieux Sérums & VaccinsInventor: Véronique Barban
-
Patent number: 6274132Abstract: A method and solution or gel composition containing activated chlorine dioxide and phosphates, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, and sodium monofluorophosphate, is disclosed for lubricating the vagina and for treating HIV. The preferred concentration ranges are between about 0.005% to about 2.0% chlorine dioxide, and between about 0.02% to about 3.0% phosphate. The phosphate compound retards escape of chlorine dioxide in the pH range of about 6.0 to 7.4, at which pH the chlorine dioxide becomes activated and releases sufficient chlorine dioxide to reduce motility and become lethal to the involved micro-organisms.Type: GrantFiled: November 3, 2000Date of Patent: August 14, 2001Assignee: Vortech, Inc.Inventor: Perry A. Ratcliff
-
Patent number: 6274146Abstract: A biologically active phytogenous proteoglycan not having hemagglutinating activity via water solution obtained by disintegration of divisible plant cells from young potato plants, Solanum tuberosum of the Family Solanaceae, fractionated and concentrated to obtain a dry substance with a molecular mass of 8.0×105-2.5×106D and the mass percentages of the following elements: nitrogen 1.12-2.48%, carbon 39.93-44.42%, hydrogen 5.15-7.21%; the remaining is an ash component, which includes a polysaccharide chain consisting of residues of neutral sugars in the amount of 34.0-85.3% and in the following mass percentages: glucose 26.4-33.1%, galacturonic acid 19.0-25.1%, arabinose 1.7-4.4%, uronic acids 12.0-18.0%, rhamnose 1.2-10.0%, xylose 0.1-3.0%, mannose 0.1-5.0%, galactose 2.5-27.0%; and up to 15 ng of pro that consists of amino acids residues in the following quantities based on ng per 0.1 mg of proteoglycan: asparagine 126.0-146.0 ng, serine 139.0-159.0 ng, glutamine 263.0-283.0 ng, glycine 117.Type: GrantFiled: April 17, 2000Date of Patent: August 14, 2001Inventor: Ludmila Chekanovskaya
-
Patent number: 6258385Abstract: The invention relates to the use of electron active molecular crystals comprising tetrasilver tetroxide (Ag4O4) for the treatment and cure of dermatological skin conditions (diseases) ranging from dermatitis, acne and psoiasis to herpes and skin ulcers.Type: GrantFiled: April 18, 2000Date of Patent: July 10, 2001Assignee: Marantech Holding, LLCInventor: Marvin S. Antelman
-
Patent number: 6242429Abstract: Antiviral Ara-A derivatives having resistance to metabolism by adenosinedeaminase (ADA) are 2-substituted arabinosyladenine derivatives represented by the formula (I) and pharmaceutically acceptable salts and hydrates thereof: wherein Z is alkyl having at least 4 carbon atoms, alkenyl or alkynyl and R is hydrogen or lower alkyl. The compounds are useful as therapeutic or preventive agents for diseases infected by DNA virus such as herpes simplex virus (HSV), herpes zoster virus, cytomegalovirus (CMV), adenovirus, hepatitis virus or vaccinia virus. As compared with Ara-A, they not only show good activity in blood with an excellent sustaining property but also are capable of being orally administered without substantial loss of pharmaceutical effectiveness due to metabolism by ADA.Type: GrantFiled: June 24, 1999Date of Patent: June 5, 2001Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Toshio Yamada, Koichi Yamanishi
-
Patent number: 6225345Abstract: The invention relates to compounds of formula (I): wherein R1 and R10 are each independently of the other lower alkoxycarbonyl; either R2, R3 and R4 are each independently of the other C1-C4alkyl and R7, R8 and R9 are each selected from hydrogen and C1-C4alkyl, with not more than 2 of the radicals being hydrogen; or R7, R8 and R9 are each independently of the other C1-C4alkyl and R2, R3 and R4 are each selected from hydrogen and C1-C4alkyl, with 1 or 2 of the radicals being hydrogen; R5 is phenyl or cyclohexyl; and R6 is phenyl or cyanophenyl; or salts thereof; those compounds are inhibitors of retroviral aspartate proteases and are effective, for example, against HIV.Type: GrantFiled: May 21, 1998Date of Patent: May 1, 2001Assignee: Novartis AGInventors: Alexander Fässler, Guido Bold, Hans-Georg Capraro, Marc Lang
-
Patent number: 6192887Abstract: Microbicidal and spermicidal methods and topical pharmaceutical compositions containing sodium dodecyl sulfate or its derivatives as active ingredients for the prevention and control of pregnancy and sexually transmitted diseases, including human papilloma viruses. Spermicidal barriers and microbial disinfectants containing the compositions are also provided.Type: GrantFiled: May 19, 1998Date of Patent: February 27, 2001Assignee: The Pennsylvania State UniversityInventors: Mary K. Howett, John W. Kreider
-
Patent number: 6174916Abstract: Methods and compositions are provided for alleviation of disease states involving plaque formation, such as are manifested in Alzheimer's Disease and other amyloid disorders, and arteriosclerotic disease. Methods for the treatment of herpes virus infections including chronic fatigue syndrome by administration of thimerosal are further provided by the invention.Type: GrantFiled: April 1, 1998Date of Patent: January 16, 2001Assignee: Milkhaus Laboratory, Ltd.Inventor: John McMichael
-
Patent number: 6172053Abstract: The present invention relates to a therapeutic composition and formulation for the treatment of viral diseases such as, Dengue fever and influenza. More particularly, to therapeutic preparation comprising substantially water soluble, local anesthetic of the ester type, procaine hydrochloride and a water soluble glucocorticoid, dexamethasone sodium phosphate.Type: GrantFiled: September 13, 1999Date of Patent: January 9, 2001Inventor: Ruben G. Fabunan
-
Patent number: 6159500Abstract: A method for the administration of glutathione orally comprising the administration of a bolus of glutathione which is pharmaceutically stabilized and encapsulated. The glutathione is administered on an empty stomach. The preferred stabilizer is ascorbic acid.Type: GrantFiled: December 31, 1997Date of Patent: December 12, 2000Assignee: Antioxidant Pharmaceuticals CorporationInventors: Harry B. Demopoulos, Myron L. Seligman
-
Patent number: 6159174Abstract: In order to prevent conception and/or the spread of sexually transmitted diseases (STD's) one or more lectins capable of binding sperm and/or the pathogenic microorganisms responsible for STD's are administered to the vagina prior to sexual intercourse. The lectins immobilize the sperm to render them incapable of fertilization and also bind to the microorganisms to render them non-pathogenic or to the cells to prevent infection by the microorganisms. Lectins can also be administered to treat sexually transmitted vaginal infections. The invention also encompasses a device for to be placed in the vault of the vagina which comprises a ring which surrounds the cervix and a membrane spanning the central aperture of the ring to prevent the direct contact of ejaculate with the cervical tissues. The device is impregnated or coated with lectins and releases them into the vaginal environment over a period of time.Type: GrantFiled: November 24, 1998Date of Patent: December 12, 2000Assignee: Legere Pharmaceuticals, Ltd.Inventors: Michael J. Oldham, Bruce F. Rose, Howard C. Krivan
-
Patent number: 6147116Abstract: The present invention relates to polyaromatic compounds having useful antiviral activity against viruses of the herpes family, to a composition containing them, and to a method of using them for the treatment of herpes viruses infections.Type: GrantFiled: May 11, 1999Date of Patent: November 14, 2000Assignee: Pharmacia & Upjohn CompanyInventors: Michael Robert Barbachyn, Fred L. Homa, Antonio Monge, Esteban Santiago, Juan J. Martinez-Irujo, Maria Font
-
Patent number: 6132756Abstract: The present invention provides a method for the prevention and treatment of viral-induced tumors, more specifically, human warts. The method uses sandalwood oil and/or derivatives from the sandalwood oil to prepare medicaments for the prevention and treatment of viral-induced tumors (i.e., warts caused by the human papillomavirus (HPV)) in humans. The method of the invention comprises the topical administration of the sandalwood oil or a composition derived therefrom to the human epidermis and/or to the genital tract as needed. The present invention is also concerned with a unique antiviral composition useful for topical application. The antiviral composition according to this invention is also effective against other DNA viruses such as the DNA pox virus that causes Molluscum contagiosum and may be effective against other DNA viruses such as AIDS virus and RNA viruses.Type: GrantFiled: September 2, 1998Date of Patent: October 17, 2000Assignee: Haque, Inc.Inventors: Malika H. Haque, Azeez U. Haque
-
Patent number: 6020005Abstract: A genital wart treatment for treating and removing genital warts. The genital wart treatment includes the acts of dissolving a volume of particulate potassium permanganate in a volume of water to form a treatment solution, and repeatedly performing over a duration of time a treatment application comprising the acts of applying the treatment solution on to genital warts and surrounding skin of a subject to wet the genital warts and surrounding skin with the treatment solution, applying a styptic to the wet genital warts and surrounding skin, and then removing an outermost layer of skin on the genital warts.Type: GrantFiled: April 8, 1999Date of Patent: February 1, 2000Inventor: Ervin G. Weathers
-
Patent number: 6015573Abstract: Compositions for topical use in herpes virus infections comprising anti-herpes nucleoside analogue phosphate esters, such as acyclovir monophosphate and acyclovir diphosphate, which show increased activity against native strains of herpes virus as well as against resistant strains, particularly thymidine kinase negative strains of virus. Also disclosed are methods for using the topical compositions in treatment of herpes disease.Type: GrantFiled: December 16, 1997Date of Patent: January 18, 2000Inventor: Karl Y. Hostetler
-
Patent number: 5989555Abstract: Larrea tridentata and Ambrosia deltoidea are shown to produce compounds that inhibit replication of HIV. The compounds can be extracted by differential fractionation and by counter-current chromatographic methods described herein. Extracts prepared from L. tridentata and A. deltoidea are found to be effective in inhibiting viral replication. The extracts from L. tridentata have been characterized and found to contain tricyclic lignans. The extracts can be administered to subjects for treatment of viral infection.Type: GrantFiled: May 2, 1996Date of Patent: November 23, 1999Inventor: John N. Gnabre
-
Patent number: 5989522Abstract: The invention relates to an oral composition for prevention of mycotic infections of the oral cavity comprising an antifungal compound embedded in a sustained release carrier such as a cellulosic polymer, and a method for the use of said composition in preventing microfungal infections in the oral cavity. The invention also provides for the supplementation of said oral composition with an adhesive and a plasticizer to increase antifungal effectiveness.Type: GrantFiled: April 6, 1995Date of Patent: November 23, 1999Assignee: Yissum Research & Development Company of the Hebrew University of JerusalemInventor: Michael Friedman
-
Patent number: 5958887Abstract: The present invention relates to the use of hymenoptera venom or proteinaceous or polypeptide components contained therein in the manufacture of a medicament for treating DNA virus infections, and to a method for treatment of mammalian DNA virus infections which uses hymenoptera venom or proteinaceous or polypeptide components contained therein.Type: GrantFiled: June 22, 1998Date of Patent: September 28, 1999Inventors: Michael Hansen, Ole Gyring Nieben
-
Patent number: 5952318Abstract: A mixture of betasitosterol and betasitosteryl glycoside in a ratio of between 1:1 and 500:1 is administered to an HIV infected individual. This has the effect of stabilizing CD4 cell numbers, decreasing the plasma viral load, degree of apoptosis in, and the serum levels of 1L6 in the peripheral blood.Type: GrantFiled: February 17, 1998Date of Patent: September 14, 1999Assignee: Rooperol (NA) NVInventor: Patrick Jacques Desire Bouic
-
Patent number: 5928645Abstract: The present invention provides a extracted substance from a mixture of a non-fat starch from Ricini semen and a root of coptis Sp. This substance is suitable for use in the therapeutic applications of AIDS.Type: GrantFiled: September 13, 1995Date of Patent: July 27, 1999Assignee: Young Bok Han & Korean Assoc. of Creation ResearchInventors: Young Bok Han, Jeong Jo Mun, Hong Ki Kyung, Jong Bae Kim, Kyung Tae Kim, Hae Ri Kim, Jeong Han Kim, Hyun Gil Shin, Kyung Rae Kim, Eun Kyung Hong, Choon Won Kim
-
Patent number: 5925365Abstract: Described is a water-in-oil type cosmetic emulsion comprising (A) an amide compound having a melting point of 0 to 50.degree. C. and (B) a nonionic surfactant having an HLB smaller than 8. The cosmetic composition according to the present invention has excellent stability, can enhance the water-retaining ability of the stratum corneum and has excellent skin-roughness lessening effects.Type: GrantFiled: October 14, 1997Date of Patent: July 20, 1999Assignee: Kao CorporationInventor: Tomoyuki Yamamoto
-
Patent number: 5916893Abstract: A method for the treatment of latent infection of herpesviruses in mammals, including humans, which method comprises administering to the mammal in need of such treatment, an effective amount of a compound of formula (A): ##STR1## or a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative of either of the foregoing.Type: GrantFiled: April 25, 1997Date of Patent: June 29, 1999Assignee: SmithKline Beecham p.l.c.Inventors: Hugh John Field, Alana Maureen Thackray, Teresa Helen Bacon, David Sutton, Richard Anthony Vere Hodge
-
Patent number: 5894019Abstract: A topically applicable pharmaceutical composition comprises at least one liquid lipid, at least one pharmaceutical active ingredient which is soluble in at least one of the liquid lipids and is re-absorbed by the skin, and a hydrous gel which is the main component of the composition, whereby at least one lipid and at least one active ingredient are worked into the gel and the composition is essentially free of emulsifying agents and solid constituents, with the exception of the necessary gelatinizing agent required to form the hydrous gel. All of the active ingredients are present in dissolved form, whereby at least one active ingredient is dissolved in the liquid lipid, and this lipid containing the dissolved active ingredient is itself the internal phase and is worked into the hydrous gel as the external phase. The composition is also essentially free of surface-active substances.Type: GrantFiled: September 17, 1997Date of Patent: April 13, 1999Assignee: GEBRO Broschek Gesellschaft m.b.H.Inventors: Ernst Hesse, Gerhard Hantich, Volker Eisenreich, Torsten Moller
-
Patent number: 5885987Abstract: This invention relates to a phenylene derivative represented by the following formula (1) or a salt thereof and also to a medicine containing it as an effective ingredient. ##STR1## wherein R.sup.1 represents H or halogen; A represents --CH.dbd.CH--, --CH.dbd.N--, --N(R.sup.2)--, --O-- or --S--; W represents --CH.dbd.CH-- or --CH.sub.2 O--; X represents --CH.sub.2 O--, --CH.sub.2 S--, --CH.sub.2 N(R.sup.3)--, --CH.dbd.N--, --COO-- or --CONH--; Y represents ##STR2## B.sup.1 represents --C(R.sup.7)(R.sup.8)(CH.sub.2).sub.l, --S(O).sub.m (CH.sub.2).sub.n -- or --CH.dbd.C(R.sup.9)--; B.sup.2 represents --CH.sub.2 CH.sub.2 -- or --CH.sub.2 CH.sub.2 CH.sub.2 --; Z.sup.1 and Z.sup.2 each represents O or S; etc. The phenylene derivative or salt thereof has antileukotrienic action and antihistaminic action and is useful as a medicine such as an asthma preventive or curative.Type: GrantFiled: November 18, 1997Date of Patent: March 23, 1999Assignee: Kowa Co., Ltd.Inventors: Henk Timmerman, Mingqiang Zhang, Kazuhiro Onogi, Masahiro Tamura, Tsutomu Toma, Yasushi Wada
-
Patent number: 5879706Abstract: A tablet comprising at least 50% w/w valaciclovir and 0.05 to 3% w/w colloidal silicon dioxide in which the valaciclovir is present within granules of the tablets and the silicon dioxide, a lubricant and a microcrystalline cellulose filler are present extragranularly has excellent hardness and friability properties while still maintaining lubrication of the tablet granules.Type: GrantFiled: August 29, 1997Date of Patent: March 9, 1999Assignee: Glaxo Wellcome Inc.Inventors: Barry Howard Carter, Lloyd Gary Tillman
-
Patent number: 5869446Abstract: A composition of lactoferrin, ovotransferrin or serotransferrin in combination with desferrioxamine methanesulfonate or other low molecular weight chelators for treating viral infections, and methods of treatment utilizing these compositions, is described.Type: GrantFiled: September 5, 1997Date of Patent: February 9, 1999Assignee: Gambit International LimitedInventors: Piera Valenti, Giovanni Antonini
-
Patent number: 5866607Abstract: Compounds of general formula (I) ##STR1## wherein n is 11, 12 or 13 and R is bromine or hydroxy, and physiologically acceptable salts thereof, with the proviso than when n is 11, R is not bromo, have been found to be effective as non-toxic agents against herpesviruses and retroviruses.Type: GrantFiled: June 11, 1997Date of Patent: February 2, 1999Assignee: BTG International LimitedInventors: David Richard Harper, Robert Andrew Jeffrey McIlhinney, Caroline Jane Blunt
-
Patent number: 5863905Abstract: Optically active antiviral compounds having the formula ##STR1## wherein m is 0, 1, 2, or 3; n and q are selected from the group of 0 and 1, provided that n and q may not both be zero; and R, R.sub.1, and R.sub.2 are independently of each other selected from the group consisting of oxygen and sulfur, provided that all R, R.sub.1 and R.sub.2, may not be oxygen, and further provided that all R, R.sub.1, and R.sub.2 may not be sulfur. The compounds possess increased antiviral activity and/or metabolic stability.Type: GrantFiled: January 8, 1997Date of Patent: January 26, 1999Assignee: Temple University-Of The Commonwealth System of Higher EducationInventors: Robert J. Suhadolnik, Wolfgang Pfleiderer
-
Patent number: 5851997Abstract: Prophylaxis against viral infections, as well as treatment for individuals infected with a virus, can be achieved through the administration of human chorionic gonadotropin (HCG). Exemplary of the viral infections that are amenable to the use of HCG in this regard include those caused by HIV-1, Kaposi's sarcoma herpes virus, molluscipoxvirus and cytomegalovirus. In addition, HCG can be used as a neonatal immune booster via administration to a baby at delivery and, optionally, for the first several months of life, until the infantile immune system matures, in order to prevent HIV transmission and control any low-level viremia, as well as to protect against various other viruses, such as herpes viruses and oncogenic viruses.Type: GrantFiled: July 2, 1996Date of Patent: December 22, 1998Inventor: Pamela Jo Harris
-
Patent number: 5840771Abstract: In order to prevent conception and/or the spread of sexually transmitted diseases (STD's) one or more lectins capable of binding sperm and/or the pathogenic microorganisms responsible for STD's are administered to the vagina prior to sexual intercourse. The lectins immobilize the sperm to render them incapable of fertilization and also bind to the microorganisms to render them non-pathogenic or to the cells to prevent infection by the microorganisms. Lectins can also be administered to treat sexually transmitted vaginal infections. The invention also encompasses a device for to be placed in the vault of the vagina which comprises a ring which surrounds the cervix and a membrane spanning the central aperture of the ring to prevent the direct contact of ejaculate with the cervical tissues. The device is impregnated or coated with lectins and releases them into the vaginal environment over a period of time.Type: GrantFiled: September 26, 1997Date of Patent: November 24, 1998Assignee: Legere Pharmaceuticals, Ltd.Inventors: Michael J. Oldham, Bruce F. Rose
-
Patent number: 5840763Abstract: A method for the treatment of latent infection of herpesviruses in mammals, including humans, which method comprises administering to the mammal in need of such treatment, an effective amount of a compound of formula (A): ##STR1## or a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative of either of the foregoing.Type: GrantFiled: September 1, 1995Date of Patent: November 24, 1998Assignee: SmithKline Beecham plcInventors: Hugh John Field, Alana Maureen Thackray, Teresa Helen Bacon, David Sutton, Richard Anthony Vere Hodge
-
Patent number: 5837729Abstract: The present invention relates to the use of acetaminophen (Tylenol) and derivatives thereof which can be used to inhibit the growth, replication and elaboration of the human immunodeficiency virus (HIV). The present invention comprises in vitro as well as in vivo methods for the prevention and/or treatment of HIV infections and acquired immune deficiency syndrome (AIDS), at doses of acetaminophen or its derivatives which are effective to inhibit the replication, growth and/or elaboration of HIV.Type: GrantFiled: April 26, 1996Date of Patent: November 17, 1998Assignee: Metatron, Inc.Inventor: Aldar S. Bourinbaiar
-
Patent number: 5827829Abstract: The present invention relates to the use of hymenoptera venom or proteinaceous or polypeptide components contained therein in the manufacture of a medicament for treating DNA virus infections, and to a method for the treatment of mammalian DNA virus infections which uses hymenoptera venom or proteinaceous or polypeptide components contained therein.Type: GrantFiled: January 21, 1997Date of Patent: October 27, 1998Inventors: Michael Hansen, Ole Gyring Nieben
-
Patent number: 5817639Abstract: The present invention provides a novel purine 4'-thioarabinonucleoside represented by the following formula ?1!: ##STR1## wherein B represents a purine base other than adenine. Also disclosed are a method for preparing the purine 4'-thioarabinonucleoside and pharmaceutical compositions containing the purine 4'-thioarabinonucleoside.Type: GrantFiled: July 12, 1996Date of Patent: October 6, 1998Assignee: Yamasa CorporationInventors: Mikari Watanabe, Yuichi Yoshimura, Shinji Sakata, Noriyuki Ashida, Haruhiko Machida
-
Patent number: 5814319Abstract: An anti-viral, anti-bacterial, and anti-cancer agent comprising as the effective component, an alkali extraction of Aspalathus linearis which is preferably obtained after extraction by hot water. The agent serves to treat and prevent bacterial infections; to treat and prevent cancer; and to treat or prevent viral infection, for example, infection caused by retroviruses, such as human T-cell leukemia and the AIDS virus. The agent has no side effects.Type: GrantFiled: March 22, 1996Date of Patent: September 29, 1998Assignee: Mitsui Norin Co., Ltd.Inventor: Masatoshi Nakano
-
Patent number: 5811423Abstract: Certain benzoxazinones are useful in the inhibition of HIV reverse transcriptase (including its resistant varieties), the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.Type: GrantFiled: March 12, 1997Date of Patent: September 22, 1998Assignee: Merck & Co., Inc.Inventors: Steven D. Young, Linda S. Payne, Susan F. Britcher, Lekhanh O. Tran, William C. Lumma, Jr.
-
Patent number: 5807552Abstract: A multimer of monomers non-covalently held together by interactive peptide linkers is provided for the enhancement of the immunogenicity of a substance. These multimers are useful for stimulating or suppressing the immune system, detecting the presence of antibodies, bypassing MHC restriction in an animal, the effective presentation of antigen, suppressing autoimmune disease, inducing cytokine production, adsorption, treating a defective immune system and for use as an adjuvant.Type: GrantFiled: August 4, 1995Date of Patent: September 15, 1998Assignee: Board of Regents, The University of Texas SystemInventors: G. John Stanton, Thomas K. Hughes, Jr., Eric M. Smith
-
Patent number: 5773027Abstract: A method is disclosed for the treatment of viral diseases comprising the administration of antiviral agents encapsulated in liposomes. Also provided are formulations of liposomes for the treatment of viral diseases and more particularly for the treatment of infections caused by viruses like human immunodeficiency virus (HIV) and cytomegalovirus (CMV). These formulations of liposomes are composed of specific classes of lipid components and contain an entrapped drug effective against the viral disease. These liposomal formulations of antiviral drugs allow high cellular penetration in different cell lines, good in vitro antiviral efficacy against HIV and CMV replication, efficient in vivo targeting of HIV reservoirs and a marked improvement of the pharmacokinetics of drugs.Type: GrantFiled: October 3, 1995Date of Patent: June 30, 1998Assignee: Michael G. BergeronInventors: Michel G. Bergeron, Andre Desormeaux
-
Patent number: 5762940Abstract: This invention relates to a method and composition for inhibiting or destroying viruses or retroviruses in a mammalian host. The method comprises contacting the viruses or retroviruses with a composition. The composition comprises an active ingredient capable of inhibiting or destroying viruses or retroviruses, for example, a surfactant, and an activating ingredient capable of inhibiting or destroying one or more enzymes associated with viruses or retroviruses, for example, a fluorinated compound capable of releasing fluoride anions, and an excipient.Type: GrantFiled: June 6, 1995Date of Patent: June 9, 1998Assignee: Atlantic Pharmaceutical Products LimitedInventors: Pierre Bourbon, Pierre Lagny, Pierre Billot
-
Patent number: 5756116Abstract: Compositions for topical use in herpes virus infections comprising anti-herpes nucleoside analogue phosphate esters, such as acyclovir monophosphate and acyclovir diphosphate, which show increased activity against native strains of herpes virus as well as against resistant strains, particularly thymidine kinase negative strains of virus. Also disclosed are methods for using the topical compositions in treatment of herpes disease.Type: GrantFiled: December 2, 1996Date of Patent: May 26, 1998Inventor: Karl Y. Hostetler
-
Patent number: 5750578Abstract: A therapeutic method is provided for treating a mammal afflicted with a herpesvirus infection comprising administering an effective amount of betulin or a derivative thereof.Type: GrantFiled: February 11, 1997Date of Patent: May 12, 1998Assignee: Regents of The University of MinnesotaInventors: Robert M. Carlson, Pavel A. Krasutsky, M. Reza-Ul Karim
-
Patent number: 5747070Abstract: Disclosed are methods for treatment of herpes virus infections in a human or lower animal subject comprising administering to the subject stannous salt and one or more pharmaceutically acceptable carriers suitable for topical administration. The stannous salt may be one or more stannous carboxylates, a stannous halide selected from the groups consisting of stannous bromide, stannous iodide, and stannous chloride dihydrate, two or more stannous halides, or one or more stannous halides and one or more stannous carboxylates. Another therapeutic agent, such as an anesthetic, analgesic, or antibiotic, may also be administered. Also disclosed are compositions effective in treating herpes virus infections in a human or lower animal subject comprising stannous fluoride, one or more therapeutic agents, and one or more pharmaceutically acceptable carriers suitable for topical administration.Type: GrantFiled: January 7, 1997Date of Patent: May 5, 1998Assignee: The Procter & Gamble CompanyInventor: Satyanarayana Majeti
-
Patent number: 5744167Abstract: Disclosed are methods for treatment of herpes virus infections in a human or lower animal subject comprising administering to the subject stannous salt and one or more pharmaceutically acceptable carriers suitable for topical administration. The stannous salt may be one or more stannous carboxylates, a stannous halide selected from the groups consisting of stannous bromide, stannous iodide, and stannous chloride dihydrate, two or more stannous halides, or one or more stannous halides and one or more stannous carboxylates. Another therapeutic agent, such as an anesthetic, analgesic, or antibiotic, may also be administered. Also disclosed are compositions effective in treating herpes virus infections in a human or lower animal subject comprising stannous fluoride, one or more therapeutic agents, and one or more pharmaceutically acceptable carriers suitable for topical administration.Type: GrantFiled: January 7, 1997Date of Patent: April 28, 1998Assignee: The Procter & Gamble CompanyInventor: Satyanarayana Majeti
-
Patent number: 5738850Abstract: The invention relates to a phytotherapeutic agent for the treatment of skin lesions and morbid skin changes. In particular, it should be suitable for functioning as an effective therapeutic agent for the treatment of herpes simplex without significant side effects.The phytotherapeutic agent consists of an extract of components extractable from sage, (Salvia officinalis), ribwort plantain (Plantago lanceolata), greater plantain (Plantago major) and mistletoe (Viscum album).Type: GrantFiled: February 10, 1997Date of Patent: April 14, 1998Inventors: Horst Walter Hendricks, Sabine Hendricks
-
Patent number: 5714516Abstract: Compounds of general formula (I) ##STR1## wherein n is 11, 12 or 13 and R is bromine or hydroxy, and physiologically acceptable salts thereof, with the proviso than when n is 11, R is not bromo, have been found to be effective as non-toxic agents against herpesviruses and retroviruses.Type: GrantFiled: December 9, 1994Date of Patent: February 3, 1998Assignee: British Technology Group LimitedInventors: David Richard Harper, Robert Andrew McIlhinney, Caroline Jane Blunt
-
Patent number: 5712257Abstract: Surfactant-stabilized ternary complexes of dsRNAs in topical pharmaceutical compositions, optionally also including a lymphokine and/or an inhibitor of reverse transcriptase, are applied topically to the affected or exposed area to treat or prevent viral infections, such as herpes virus, and other infectious conditions, particularly venereally transmitted pathogens. Ternary complexes of two strands of complementary RNA plus a compatible surfactant stabilized against temperature-associated enzymatic inactivation are described.Type: GrantFiled: May 23, 1995Date of Patent: January 27, 1998Assignee: HEM Research, Inc.Inventor: William A. Carter
-
Patent number: 5700781Abstract: Prophylaxis against HIV, treatment for individuals infected with HIV, and treatment Kaposi's sarcoma can be effected, respectively, through the administration of human chorionic gonadotropin.Type: GrantFiled: November 10, 1994Date of Patent: December 23, 1997Inventor: Pamela Jo Harris
-
Patent number: 5696160Abstract: Multiple daily applications of a topical composition having as the active ingredients an anesthetic and a surfactant with anti-viral activity decrease the time of healing of herpes simplex viral lesions from approximately seven to ten days to five to six days, as well as decrease inflammation and pain. The composition is applied to the lesions daily, approximately every four hours, preferably beginning at the prodromal stage of infection. Relief is almost immediate, and is characterized by decreased pain, swelling, and more rapid healing as compared with the untreated lesion.Type: GrantFiled: October 14, 1994Date of Patent: December 9, 1997Assignee: Virotex CorporationInventors: Bruce W. Miller, Richard L. Kronenthal
-
Patent number: 5688791Abstract: Disclosed are an aryl group- or heterocyclic group-substituted aminoquinolone compound represented by the formula (Ia), (Ib) or (Ic): ##STR1## wherein each of the substitutents are defined in the specification, or a salt of the compound, and an AIDS curing agent containing the same as an effective ingredient.Type: GrantFiled: September 11, 1995Date of Patent: November 18, 1997Assignee: UBE Industries, LTD.Inventors: Tomio Kimura, Tetsushi Katsube